Oncology Institute (TOI) Cash from Financing Activities (2020 - 2026)

Oncology Institute (TOI) has reported Cash from Financing Activities for 7 consecutive years, with -$28000.0 the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$28000.0, up 99.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (up 323.05% YoY), and the FY2025 annual result was $11.6 million, up 430.96% from the prior year.
• Cash from Financing Activities was -$28000.0 for Q1 2026 at Oncology Institute, down from $3.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $105.4 million in Q3 2022 and troughed at -$10.7 million in Q2 2022.
• Average Cash from Financing Activities over 5 years is $5.5 million, with a median of -$847000.0 recorded in 2022.
• Year-over-year, Cash from Financing Activities surged 1317537.5% in 2022 and slumped 405.33% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$847000.0 in 2022, then slumped by 110.27% to -$1.8 million in 2023, then surged by 90.79% to -$164000.0 in 2024, then jumped by 2376.83% to $3.7 million in 2025, then tumbled by 100.75% to -$28000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$28000.0 in Q1 2026, $3.7 million in Q4 2025, and $10.6 million in Q3 2025.